Hinde Group, an investment management company, has released its first-quarter 2026 investor letter. A copy of the letter is available to download here. The portfolio delivered a gross return of 3.80% and a net return of 3.41% in the first quarter, compared to a -4.33% return for the S&P 500 Index. The first quarter began with the SaaS-pocalypse, followed by military actions against Iran, leading to increased volatility in the financial markets. The ongoing uncertainty regarding the conflict’s duration and economic implications has continued to affect global financial markets as the quarter came to a close. Nevertheless, the portfolio remains well-equipped to navigate these challenging conditions. Typically, periods of disruption and change offer the most promising investment opportunities. In addition, please check the firm’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Hinde Group highlighted stocks like Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is a leading medical technology company that engages in the medical supplies, devices, laboratory equipment, and diagnostic products. On May 28, 2026, Becton, Dickinson and Company (NYSE:BDX) closed at $148.41 per share. One-month return of Becton, Dickinson and Company (NYSE:BDX) was -0.60%, and its shares gained 9.42% over the past 52 weeks. Becton, Dickinson and Company (NYSE:BDX) has a market capitalization of $40.89 billion.
Hinde Group stated the following regarding Becton, Dickinson and Company (NYSE:BDX) in its Q1 2026 investor letter:
“This quarter’s portfolio update covers our position in Becton, Dickinson and Company (NYSE:BDX). BDX is a special situation investment that we initiated in July 2025.
Becton Dickinson (“BD”) develops, manufactures and sells a diversified range of medical supplies and devices. BD’s products are used by hospitals, doctors, the pharmaceutical industry and individuals. Ninety percent of hospital patients encounter at least one of the more than 45 billion medical products BD manufactures each year. Roughly 60% of Becton Dickinson’s $18.5 billion of revenue comes from the U.S. and around a quarter comes from Europe.
On February 9th, Becton Dickinson completed its Reverse Morris Trust transaction with Waters Corporation. BD spun off its Biosciences & Diagnostics Solutions business, and that business simultaneously merged with Waters Corporation. As consideration, BD received $4 billion in cash and Becton Dickinson shareholders received 0.135 shares of Waters Corporation common stock (NYSE: WAT) for each share of BDX they held…” (Click here to read the full text)
Becton, Dickinson and Company (NYSE:BDX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 48 hedge fund portfolios held Becton, Dickinson and Company (NYSE:BDX) at the end of the fourth quarter, up from 45 in the previous quarter. Becton, Dickinson and Company (NYSE:BDX) reported revenue of $4.7 billion in the second quarter of fiscal 2026, marking an increase of 2.6% year-over-year on a FXN basis. While we acknowledge the risk and potential of Becton, Dickinson and Company (NYSE:BDX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Becton, Dickinson and Company (NYSE:BDX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Becton, Dickinson and Company (NYSE:BDX) and shared the list of best rising dividend stocks to buy. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
